New combo therapy aims to outsmart drug-resistant breast cancer
NCT ID NCT06062498
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times
Summary
This study compares the hormone therapy elacestrant alone versus elacestrant combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) in 174 people with ER+/HER2- advanced or metastatic breast cancer who have already used a CDK4/6 inhibitor. The goal is to see if the combination delays cancer progression better than elacestrant alone. Participants will be monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.